• Christopher J. Bulpitt
Part of the Developments in Biostatistics and Epidemiology book series (DBEP, volume 1)


Myocardial Infarction Tienilic Acid Hypertension Detection Coronary Drug Project European Working Party 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bradford Hill, A. The clinical trial. Br. Med. Bull. 7:278–282, 1951.Google Scholar
  2. 2.
    Cochrane, A.L. Effectiveness and efficiency: Random reflections on health services. London, The Nuffield Provincial Hospital Trust, 1972.Google Scholar
  3. 3.
    Medical Research Council investigation. Streptomycin treatment of pulmonary tuberculosis. Br. Med. J. 2:769–782, 1948. Material reproduced with permission.CrossRefGoogle Scholar
  4. 4.
    Doll, R., and Peto, R. Randomised controlled trials and retrospective controls: Br. Med. J. 44:280, 1980.Google Scholar
  5. 5.
    Rose, G. Bias. Br. J. Clin. Pharmacol. 13:157–162, 1982.PubMedCrossRefGoogle Scholar
  6. 6.
    L’Etang, J.C. Historical aspects of drug evaluation. In: The principles and practice of clinical trials, Harris, E.L., and Fitzgerald, J.D. (eds.). Edinburgh and London, E. and S. Livingstone, 1970. Pp. 3–6.Google Scholar
  7. 7.
    Bull, J.P. The historical development of clinical therapeutic trials. J. Chronic Dis. 10:218–248, 1959.PubMedCrossRefGoogle Scholar
  8. 8.
    Bradford Hill, A. Statistical methods in clinical and preventive medicine. Edinburgh and London, E. and S. Livingstone, 1962.Google Scholar
  9. 9.
    Maitland, C. Account of inoculating the smallpox. London, J. Robertson, 1972.Google Scholar
  10. 10.
    Williams, W. Masters of medicine. London, Pan Books, 1954. P. 23.Google Scholar
  11. 11.
    Jenner, E. An inquiry into the cause and effects of the variolae vaccinae. London, S. Low, 1798.Google Scholar
  12. 12.
    Pearson, G. An inquiry concerning the history of cowpox. London, J. Johnson, 1798.Google Scholar
  13. 13.
    Waterhouse, B. A prospect of exterminating the small pox. Boston, Cambridge, 1800.Google Scholar
  14. 14.
    Haygarth, J. Of the imagination as a cause and cure of disorders of the body. new ed. Bath, R. Crutwell, 1801. P. 3.Google Scholar
  15. 15.
    Sutton, H.G. Cases of rheumatic fever treated for the most part by mint water. Guy’s Hosp. Rep. 2:392–428, 1865.Google Scholar
  16. 16.
    Laplace, P.S. Théorie analytique des probabilités. Paris, 1812.Google Scholar
  17. 17.
    Louis, P.C.A. Essay on clinical instruction. Translated by Martin P. London, S. Highley, 1834.Google Scholar
  18. 18.
    Louis, P.C.A. Recherches sur les effects de la saignée. Paris, De Mignaret, 1835.Google Scholar
  19. 19.
    Bartlett, E. An essay on the philosophy of medical science. Philadelphia, Lea and Blanchard, 1844.Google Scholar
  20. 20.
    Lister, J. On the effects of the antiseptic system upon the salubrity of a surgical hospital. Lancet 1:4 and 40, 1870.CrossRefGoogle Scholar
  21. 21.
    Pocock, S.J. Randomised controlled trials [letter]. Br. Med. J. 1:1661, 1977.PubMedCrossRefGoogle Scholar
  22. 22.
    Vallery-Radot, P. Pasteur 1822–1895. Paris, 1922.Google Scholar
  23. 23.
    Fibiger, J. Om serumbehandling af Difteri. Hosp. Tid., Kjøbenh 4:6, 309, 337, 1898.Google Scholar
  24. 24.
    Porrit, A.E., and Mitchell, G.A.G. An investigation into the prophylaxis and treatment of wound infection. In: Penicillin therapy and control in 21 army group. London, 21 Army Group, 1945. P.7.Google Scholar
  25. 25.
    Amberson, J.B., McMahon, B.T., and Pinner, M. Clinical trials of sanocrysin in pulmonary tuberculosis. Am. Rev. Tuberc. 24:401–435, 1931.Google Scholar
  26. 26.
    Glaser, E.M. Ethical aspects of clinical trials. In: The principles and practice of clinical trials, Harris E.L. and Fitzgerald, J.D. (eds.), Edinburgh and London, E. and S. Livingstone, 1970.Google Scholar
  27. 27.
    Wade, O.L. Human experiment 2, clinical aspects. In: Dictionary of medical ethics, Duncan, A.S., Dunstan, G.R., and Welbourn, R.B. (eds.). London, Darton Longman and Todd, 1977.Google Scholar
  28. 28.
    Mitscherlich A., and Mielke, F. Doctors of infamy: The story of the nazi medical crimes. New York, Shuman, 1949. Pp. xxiii–xxv.Google Scholar
  29. 29.
    World Medical Association. Human experimentation, code of ethics of the World Medical Association. Declaration of Helsinki. Br. Med. J. 2:177, 1964.CrossRefGoogle Scholar
  30. 30.
    Bradford Hill, A. Medical ethics and controlled trials. Br. Med. J. 1:1043–1049, 1963. Material reproduced with permission of author and editors of Br. Med. J. CrossRefGoogle Scholar
  31. 31.
    Medical Research Council. Responsibility in investigations on human subjects. Br. Med. J. 2:178–180, 1964.CrossRefGoogle Scholar
  32. 32.
    Committee Appointed by the Royal College of Physicians of London: Supervision of the Ethics of Clinical Investigations in Institutes. Br. Med. J. 2:429–430, 1967. Later report published by the college: Report of committee on the supervision of the ethics of clinical investigation in institutions. London, 1973.Google Scholar
  33. 33.
    Report of a Committee Appointed by Governor Dwight H. Green of Illinois. Ethics governing the service of prisoners as subjects in medical experiments. JAMA 136:457–458, 1948.CrossRefGoogle Scholar
  34. 34.
    Zelen, M. A new design for randomized clinical trials. N. Engl. J. Med. 300:1242–1245, 1979.PubMedCrossRefGoogle Scholar
  35. 35.
    Beecher, H.K. Ethics and clinical research. N. Engl. J. Med. 274:1354–1360, 1966.PubMedCrossRefGoogle Scholar
  36. 36.
    Beecher, H.K. Pain, placebos and physicians. Practitioner 189:141–155, 1962.PubMedGoogle Scholar
  37. 37.
    Veterans Administration Co-operative Study Group on Anti-Hypertensive Agents. Effects of treatment on morbidity in hypertension. II Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 213:1143–1152, 1970.CrossRefGoogle Scholar
  38. 38.
    Beecher, H.K. Surgery as placebo: A quantitative study of bias. JAMA 176:1102–1107, 1961. Material reproduced with permission. Copyright 1961, American Medical Association.PubMedCrossRefGoogle Scholar
  39. 39.
    Cobb, L.A., et al. An evaluation of internal-mammary-artery ligation by a double-blind technique. N. Engl. J. Med. 260:1115–1118, 1959.PubMedCrossRefGoogle Scholar
  40. 40.
    Dimond, E.G., Kittle, C.F., and Crockett, J.E. Evaluation of internal-mammary artery ligation and sham procedure in angina pectoris. Circulation 18:712–713, 1958.Google Scholar
  41. 41.
    Adams, R. Internal-mammary-ligation for coronary insufficiency: An evaluation. N. Engl. J. Med. 258:113–115, 1958.PubMedCrossRefGoogle Scholar
  42. 42.
    Fish, R.C., Grymes, T.P., and Lovell, M.G. Internal-mammary-artery ligation for angina pectoris: Its failure to produce relief. N. Engl. J. Med. 259:418–420, 1958.PubMedCrossRefGoogle Scholar
  43. 43.
    Amery, A., et al. Antihypertensive therapy in elderly patients: Pilot trial of the European Working Party on high blood pressure in the elderly. Gerontology 23:426–437, 1977.PubMedCrossRefGoogle Scholar
  44. 44.
    McPherson, K. Statistics: The problem of examining accumulating data more than once. N. Engl. J. Med. 290:501–502, 1974.PubMedCrossRefGoogle Scholar
  45. 45.
    Coronary Drug Project Research Group: The Coronary Drug Project. JAMA 214:1303–1313, 1970.CrossRefGoogle Scholar
  46. 46.
    University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 19, suppl. 2:747–830, 1970.Google Scholar
  47. 47.
    Veterans Administration Co-operative Study Group on Anti-hypertensive Agents: Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA 202:1028–1034, 1967.CrossRefGoogle Scholar
  48. 48.
    The Anturane Reinfarction Trial Research Group: Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. N. Engl. J. Med. 298:289–295, 1978.CrossRefGoogle Scholar
  49. 49.
    Bulpitt, C.J., Semmence, A., and Whitehead, T. Blood pressure and biochemical risk factors. Acta Cardiol. 33:109–110, 1978.Google Scholar
  50. 50.
    Committee of Principal Investigators: A Cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br. Heart J. 40:1069–1118, 1978.CrossRefGoogle Scholar
  51. 51.
    Elwood, P.C., et al. A randomised controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br. Med. J. 1:436–440, 1974.PubMedCrossRefGoogle Scholar
  52. 52.
    An International Anticoagulant Review Group. Collaborative analysis of long-term anticoagulant administration after acute myocardial infarction. Lancet 1:203–209, 1970.Google Scholar
  53. 53.
    A progress report of the European Working Party on High Blood Pressure in the Elderly (EWPHE). Cardiac and Renal Function with increasing Age in Elderly Hypertensives. In: Mild hypertension: Natural history and management, Gross, F. and Strasser, T. (eds.). Tunbridge Wells, Pitman Medical, 1979. Pp. 181–197.Google Scholar
  54. 54.
    Amery, A., et al. Glucose intolerance during diuretic therapy: Results of trial by the European Working party on Hypertension in the Elderly. Lancet 1:681–683, 1978.PubMedCrossRefGoogle Scholar
  55. 55.
    Fowler, F.G. and Fowler, H.W. The Pocket Oxford Dictionary of Current English, SR ed. Oxford Clarendon Press, 1969.Google Scholar
  56. 56.
    Rose, G., and Hamilton, P.J.S. A randomised controlled trial of the effect on middle-aged men of advice to stop smoking. J. Epidemiol. Community Health 32:275–281, 1978.PubMedCrossRefGoogle Scholar
  57. 57.
    Veterans Administration Co-operative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: II. Influence of age, diastolic pressure, and prior cardiovascular disease: Further analysis of side effects. Circulation 45:991–1004, 1972.CrossRefGoogle Scholar
  58. 58.
    Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program: II. Mortality by race, sex, and age. JAMA 242:2572–2577, 1979.CrossRefGoogle Scholar
  59. 59.
    Meier, P. Terminating a trial—The ethical problem. Clin. Pharmacol. Ther. 25:633–640, 1979.PubMedGoogle Scholar
  60. 60.
    Stamler, J. When and how to stop a clinical trial: Invited remarks. Clin. Pharmacol. Ther. 25:651–654, 1979.PubMedGoogle Scholar
  61. 61.
    Benedict, G.W. LRC Coronary Prevention Trial: Baltimore. Clin. Pharmacol. Ther. 25, 685–687, 1979.PubMedGoogle Scholar
  62. 62.
    Schoenberger, J.A. Recruitment to the Coronary Drug Project and the Aspirin Myocardial Infarction Study. Clin. Pharmacol. Ther. 25:681–684, 1979.PubMedGoogle Scholar
  63. 63.
    Croke, G. Recruitment for the National Co-operative Gallstone study. Clin. Pharmacol. Ther. 25:691–694, 1979.PubMedGoogle Scholar
  64. 64.
    Prout, T.E. Patient recruitment: Other examples of recruitment and solutions. Clin. Pharmacol. Ther. 25:695–696, 1979.PubMedGoogle Scholar
  65. 65.
    Zelen, M. The randomisation and stratification of patients to clinical trials. J. Chron. Dis. 27:365–375, 1974.PubMedCrossRefGoogle Scholar
  66. 66.
    Wright, I.S., Marple, C.D., and Beck, D.F. Myocardial Infarction. Its clinical manifestation and treatment with anticoagulants. New York, Grune and Stratton, 1954. Pp. 8–10.Google Scholar
  67. 67.
    Weinstein, M.C. Allocation of subjects in medical experiments. N. Engl. J. Med. 291:1278–1285, 1974. Material reproduced with permission.PubMedCrossRefGoogle Scholar
  68. 68.
    Ederer, F. Patient bias, investigator bias and the double-masked procedure in clinical trials. Aw. J. Med. 58:295–299, 1975.CrossRefGoogle Scholar
  69. 69.
    Peto, R. Clinical trial methodology. Biomedicine Special No: 24-36, 1978.Google Scholar
  70. 70.
    Peto, R., et al. Design and analysis of randomised clinical trial requiring prolonged observation of each patient. I. Introduction and design. Br. J. Cancer 34:585–612, 1976.PubMedCrossRefGoogle Scholar
  71. 71.
    Roethlisberges, F.G., and Dickson, W.J. Management and the worker. An account of a research program conducted by the Western Electric Company, Hawthorne Works, Chicago. Cambridge, Mass., Harvard University Press, 1946.Google Scholar
  72. 72.
    Beecher, H.K. The powerful placebo. JAMA 159:1602–1606, 1955.CrossRefGoogle Scholar
  73. 73.
    Keats, A.S., Beecher, H.K., and Mosteller, F.C. Measurement of pathological pain in distinction to experimental pain. J. Appl. Physiol. 3:34–44, 1950.Google Scholar
  74. 74.
    Keats, A.S., D’Alessandro, G.L. and Beecher, H.K. Report to the council on pharmacy and chemistry. JAMA 147:1761–1776, 1951.CrossRefGoogle Scholar
  75. 75.
    Beecher, H.K., et al. Field use of methodone and levo-iso-methadone in a combat zone. U.S. Armed Forces Med. J. 2:1269–1276, 1951.PubMedGoogle Scholar
  76. 76.
    Lasagne, L., et al. Study of placebo response. Am. J. Med. 16:770–779, 1954.CrossRefGoogle Scholar
  77. 77.
    Beecher, H.K., et al. Effectiveness of oral analgesics (morphine, codeine, acetylsalicylic acid) and problem of placebo ‘reactors’ and ‘non reactors’. J. Pharmacol. Exp. Ther. 109:393–400, 1953.PubMedGoogle Scholar
  78. 78.
    Travell, J., et al. Comparison of effects of alpha-tocopherol and matching placebo on chest pain in patients with heart disease. Ann. N.Y. Acad. Sci. 52:345–353, 1949.Google Scholar
  79. 79.
    Evans, W., and Hoyle, C. Comparative value of drugs used in continuous treatment of angina pectoris. Q. J. Med. 2:311–338, 1933.Google Scholar
  80. 80.
    Greiner, T., et al. Method for evaluation of effects of drugs on cardiac pain in patients with angina of effort; study of khellin (visamin). Am. J. Med. 9:143–155, 1950.PubMedCrossRefGoogle Scholar
  81. 81.
    Bulpitt, C.J. Heparin as an analgesic in myocardial infarction. A double-blind trial. Br. Med. J. 3:279–281, 1967.PubMedCrossRefGoogle Scholar
  82. 82.
    Jellinek, E.M. Clinical tests on comparative effectiveness of analgesic drugs. Biomet. Bull. 2:87–91, 1946.CrossRefGoogle Scholar
  83. 83.
    Gravenstein, J.S., Devloo, R.A., and Beecher, H.K. Effect of antitussive agents on experimental and pathological cough in man. J. Appl. Physiol. 7:119–139, 1954.PubMedGoogle Scholar
  84. 84.
    Hillis, B.R. The assessment of cough-suppressing drugs. Lancet 1:1230–1235, 1952.PubMedCrossRefGoogle Scholar
  85. 85.
    Shapiro, A.K. Factors contributing to the placebo effect. Their implications for psychotherapy. Am. J. Psychother. 18:suppl. 1, 73–88, 1964.PubMedGoogle Scholar
  86. 86.
    Dollery, C.T. A bleak outlook for placebos (and for science). Eur. J. Clin. Pharmacol. 15:219–221, 1979.PubMedCrossRefGoogle Scholar
  87. 87.
    Byar, D.P., et al. Randomised clinical trials. Perspectives on some recent ideas. N. Engl. J. Med. 295:74–80, 1976.PubMedCrossRefGoogle Scholar
  88. 88.
    Christie, D. Before-and-after comparisons: a cautionary role. Br. Med. J. 2:1629–1630, 1979.PubMedCrossRefGoogle Scholar
  89. 89.
    Doll, R., and Peto, R. Mortality in relation to smoking: 20 years’ observation on male British doctors. Br. Med. J. 2:1525–1536, 1976.PubMedCrossRefGoogle Scholar
  90. 90.
    Ballintine, E.J. Randomized controlled clinical trial. National Eye Institute workshop for ophthalmologists. Objective measurements and the double-masked procedure. Am. J. Ophthalmol. 79:763–767, 1975.PubMedGoogle Scholar
  91. 91.
    Pozdena, R.F. Versuche über Blondlots ‘Emission Pesante’. Ann Physik. 17:104, 1905.CrossRefGoogle Scholar
  92. 92.
    Seabrook, W. Doctor Wood. New York, Harcourt, Brace, 1941. P. 234.Google Scholar
  93. 93.
    Fletcher, C.M. Criteria for diagnosis and assessment in clinical trials. In: Controlled clinical trials, Hill, A.B. (ed.). Springfield, 111., Charles C. Thomas, 1960.Google Scholar
  94. 94.
    Kahn, H.A., et al. Serum cholesterol: its distribution and association with dietary and other variables in a survey of 10,000 men. Isr. J. Med. Sci. 5:1117–1127, 1969.PubMedGoogle Scholar
  95. 95.
    Wilson, E.B. An introduction to scientific research. New York, McGraw-Hill, 1952.Google Scholar
  96. 96.
    Bearman, J.E., Loewenson, R.B., and Gullen, W.H. Muench’s postulates, laws, and corollaries or Biometricians’ views on clinical studies. Biometrics note 4, National Eye Institute, Bethesda, Md., 1974.Google Scholar
  97. 97.
    Foulds, G.A. Clinical research in psychiatry. J. Ment. Sci. 104:259, 1958.PubMedGoogle Scholar
  98. 98.
    Report of a co-operative randomised controlled trial. Control of moderately raised blood pressure. Br. Med. J. 3:434–436, 1973. Material reproduced with permission.CrossRefGoogle Scholar
  99. 99.
    Knowelden, J. In: Prophylactic trials, medical surveys and clinical trials, Witts, L.J. (ed.). London, Oxford University Press, 1959.Google Scholar
  100. 100.
    National Diet-Heart Study Research Group. The National Diet-Heart Study. Circulation 37, suppl. 1:1253–1259, 1968.Google Scholar
  101. 101.
    Pearson, R.M., Bulpitt, C.J., and Havard, C.W.H. Biochemical and haematological changes induced by tienilic acid combined with propranolol in essential hypertension. Lancet 1:697–699, 1979.PubMedCrossRefGoogle Scholar
  102. 102.
    U.S. Department of Health, Education and Welfare. National Institutes of Health. Cold study reveals some vitamin C influence; more research needed. Bethesda, Md. NIH Record 25:4, 197Google Scholar
  103. 103.
    Heaton-Ward, W.A. Influence and suggestion in a clinical trial (Niamid in mongolism). J. Ment. Sci. 108:865–870, 1962.Google Scholar
  104. 104.
    Abraham, H.C., et al. A controlled clinical trial of imipramine (Tofranil) with outpatients. Br. J. Psychiatry 109:286–293, 1963.PubMedCrossRefGoogle Scholar
  105. 105.
    Report to the Medical Research Council by its clinical psychiatry committee: Clinical trial of the treatment of depressive illness. Br. Med. J. 1:881–886, 1965.CrossRefGoogle Scholar
  106. 106.
    Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Randomised controlled trial of treatment for mild hypertension: design and pilot trial. Br. Med. J. 1:1437–1440, 1977.CrossRefGoogle Scholar
  107. 107.
    Report by the Mangement Committee. Initial results of the Australian Therapeutic Trial in mild hypertension. Clin. Sci. 57:449s–452s, 1979.Google Scholar
  108. 108.
    Cooper, G.R. The World Health Organization Centre for Disease Control Lipid Standardization Program. In: Quality control in chemistry. Berlin, Walter de Gruyter and Co., 1976. Pp. 97–105.Google Scholar
  109. 109.
    Rogot, E., and Goldberg, I.D. A proposed index for measuring agreement in test-retest studies. J. Chron. Dis. 19:991–1006, 1966.PubMedCrossRefGoogle Scholar
  110. 110.
    Bulpitt, C.J., Dollery, C.T., and Carne, S. Change in symptoms of hypertensive patients on referral to hospital clinic. Br. Heart J. 38:121–128, 1976.PubMedCrossRefGoogle Scholar
  111. 111.
    Galton, F. Regression towards mediocrity in hereditary stature. J. Anthropological Inst. 15:246–263, 1886.Google Scholar
  112. 112.
    Ferris, F.L., and Ederer, F. External monitoring in multiclinic trials: Application from ophthalmologic studies. Clin. Pharmacol. Ther. 25:720–723, 1979.PubMedGoogle Scholar
  113. 113.
    Wright, B.M., and Dore, C.F. A random-zero sphygmomanometer. Lancet 1:337–338, 1970.PubMedGoogle Scholar
  114. 114.
    Rose, G.A., Holland, W.W., and Crowley, F.A. A sphygmomanometer for epidemiologists. Lancet 1:296–300, 1964.PubMedCrossRefGoogle Scholar
  115. 115.
    Kahn, H.A., et al. Standardising diagnostic procedures. Am. J. Ophthalmol. 79:768–775, 1975.PubMedGoogle Scholar
  116. 116.
    Williams, O.D. A framework for the quality assurance of clinical data. Clin. Pharmacol. Ther. 25:700–702, 1979.PubMedGoogle Scholar
  117. 117.
    Schwartz, D., Flamant, R., and Lellouch, J. Clinical trials. Translated by M.J.R. Healy. London, Academic Press, 1980. Pp. 29-33.Google Scholar
  118. 118.
    Hamilton, M., Thompson, E.M., and Wisniewski, T.K. The role of blood pressure control in preventing complications of hypertension. Lancet 1:235–238, 1964.PubMedCrossRefGoogle Scholar
  119. 119.
    Clark, C.J. and Downie, C.C. A method for the rapid determination of the number of patients to include in a controlled clinical trial. Lancet 2:1357–1358, 1966.PubMedCrossRefGoogle Scholar
  120. 120.
    Coronary Drug Project Research Group. The Coronary Drug Project: Design, methods and baseline results. Circulation 47 and 48, suppl. 1:12–137, 1973.Google Scholar
  121. 121.
    National Diet-Heart Study Report. Appendix Aa-c. Sample size estimates for medical trials. Circulation 37 and 38, suppl.:1279–1308, 1968.Google Scholar
  122. 122.
    Rose, G.A. Beta-blockers in immediate treatment of myocardial infarction. Br. Med. J. 280:1088, 1980.PubMedCrossRefGoogle Scholar
  123. 123.
    Baber, N.S., and Lewis, J.A. Beta-blockers in the treatment of myocardial infarction (letter). Br. Med. J. 3:59, 1980.CrossRefGoogle Scholar
  124. 124.
    Schwartz, D., and Lellouch, J. Explanatory and pragmatic attitudes in therapeutical trials. J. Chron. Dis. 20:637–648, 1967.PubMedCrossRefGoogle Scholar
  125. 125.
    Halperin, M., et al. Sample sizes for medical trials with special reference to long-term therapy. J. Chron. Dis. 21:13–24, 1968.PubMedCrossRefGoogle Scholar
  126. 126.
    George, S.L., and Desu, M.M. Planning the size and duration of a clinical trial studying the time to some critical event. J. Chron. Dis. 27:15–24, 1974.PubMedCrossRefGoogle Scholar
  127. 127.
    Sondik, E.J., Brown, B.W., and Silvers, A. High risk subjects and the cost of large field trials. J. Chron. Dis. 27:177–187, 1974.PubMedCrossRefGoogle Scholar
  128. 128.
    Cochran, W.G. Sampling techniques. New York: Wiley, 1963. P. 145.Google Scholar
  129. 129.
    Nam, J.M. Optimum sample sizes for the comparison of the control and treatment. Biometrics 29:101–108, 1973.PubMedCrossRefGoogle Scholar
  130. 130.
    Gail, M., et al. How many controls? J. Chron. Dis. 29:723–731, 1976.PubMedCrossRefGoogle Scholar
  131. 131.
    Dunnett, C.W. Multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50:1096, 1955.CrossRefGoogle Scholar
  132. 132.
    Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. 1. Reduction in mortality of persons with high blood pressure including mild hypertension. JAMA 242:2562–2571, 1979.CrossRefGoogle Scholar
  133. 133.
    Hills, M., and Armitage, P. The two-period cross-over clinical trial. Br. J. Clin. Pharmacol. 8:7–20, 1979.PubMedCrossRefGoogle Scholar
  134. 134.
    Meier, P., and Free, S.M. Further consideration of methodology in studies of pain relief. Biometrics 27:576–583, 1961.CrossRefGoogle Scholar
  135. 135.
    Fisher, R.A. In: The design of experiments. Edinburgh, Oliver and Boyd, 1947.Google Scholar
  136. 136.
    Wilson, C., Pollock, M.R., and Harris, A.D. Diet in the treatment of infective hepatitis. Therapeutic trial of cysteine and variation of fat-content. Lancet 1:881–883, 1946.PubMedCrossRefGoogle Scholar
  137. 137.
    Aenishänslin, W., et al. Antihypertensive therapy with adrenergic beta-receptor blockers and vasodilators. Eur. J. Clin. Pharmacol. 4:177–181, 1972.PubMedCrossRefGoogle Scholar
  138. 138.
    Pearson, R.M., et al. Trial of combination of guanethidine and oxprenolol in hypertension. Br. Med. J. 1:933–936, 1976.PubMedCrossRefGoogle Scholar
  139. 139.
    Chalmers, J., et al. Effects of timolol and hydrochlorothiazide on blood-pressure and plasma renin activity. Double-blind factorial trial. Lancet 2:328–331, 1976.PubMedCrossRefGoogle Scholar
  140. 140.
    Lynch, P., et al. Objective assessment of anti-anginal treatment: a double-blind comparison of propranolol, nifedipine and their combination. Br. Med. J. 1:184–187, 1980.CrossRefGoogle Scholar
  141. 141.
    Williams, E.F. Experimental designs balanced for the estimation of residual effects of treatments. Aust. J. Sci. Res. Assoc. 2:149–168, 1949.Google Scholar
  142. 142.
    Cochran, W.G., and Cox, G.M. In: Experimental designs, 2nd ed. New York, Wiley & Sons, 1957. P. 133.Google Scholar
  143. 143.
    Armitage, P. Sequential medical trials. Oxford, Blackwell Scientific Publications, 1960.Google Scholar
  144. 144.
    Wald, A. Sequential analysis. New York, Wiley, 1947.Google Scholar
  145. 145.
    Robertson, J.D., and Armitage, P. Comparison of two hypotensive agents. Anaesthesia 14:53–64, 1959.PubMedCrossRefGoogle Scholar
  146. 146.
    Snell, E.S., and Armitage, P. Clinical comparison of diamorphine and pholcodine as cough suppressants, by a new method of sequential analysis. Lancet 1:860–862, 1957.CrossRefGoogle Scholar
  147. 147.
    Anscombe, F.J. Fixed sample-size analysis of sequential observations. Biometrics 10:98–100, 1954.CrossRefGoogle Scholar
  148. 148.
    Cochran, W.G. Newer statistical methods. In: Quantitated methods in human pharmacology and therapeutics, Lawrence, D.R. (ed.). London, Pergamon, 1959. Pp. 119–143.Google Scholar
  149. 149.
    Zelen, M. Play the winner rule and the controlled clinical trial. J. Am. Stat. Assoc. 64:131–146, 1969.CrossRefGoogle Scholar
  150. 150.
    Meier, P. Terminating a trial—the ethical problem. Clin. Pharmacol. Ther. 25:633–640, 1979.PubMedGoogle Scholar
  151. 151.
    Chalmers, T.C. When and how to stop a clinical trial: Invited remarks. Clin. Pharmacol. Ther. 25:649–650, 1979.PubMedGoogle Scholar
  152. 152.
    Hill, C., and Sancho-Garnier, H. The two-armed bandit problem, a decision theory approach to clinical trials. Biomedicine 28 42–43, 1978.PubMedGoogle Scholar
  153. 153.
    Bearman, J.E. Randomized controlled clinical trial. National Eye Institute Workshop for Ophthalmologists. Writing the protocol for a clinical trial. Am. J. Ophthalmol. 79:775–778, 1975.PubMedGoogle Scholar
  154. 154.
    McFate Smith, W. Problems in long-term trials. In: Mild hypertension: Natural history and management. Gross, F. and Strasser, T. (eds.). Pitman Medical. Tunbridge Wells, England, 1979. Pp. 244–255.Google Scholar
  155. 155.
    Spriet, A., and Simon, P. Questions à se poser pour vérifier un protocole d’essai thérapeutique avant d’en entreprendre l’exécution. Thérapie 32:633–642, 1977.PubMedGoogle Scholar
  156. 156.
    Clinical Trials Unit, Department of Pharmacology and Therapeutics, London Hospital Medical College. Aide-mémoire for preparing clinical trial protocols. Br. Med. J. 1:1323–1324,1977.Google Scholar
  157. 157.
    Hamilton, M. Computer programmes for the medical man: A solution. Br. Med. J. 2:1048–1050, 1965.PubMedCrossRefGoogle Scholar
  158. 158.
    Wright, P., and Haybittle, J. Design of forms for clinical trials (1), (2) and (3). Br. Med. J. 2:529–530, 590-592, 650-651, 1979.PubMedCrossRefGoogle Scholar
  159. 159.
    Bulpitt, C.J., Dollery, C.T., and Carne, S. A symptom questionnaire for hypertensive patients. J. Chron. Dis. 27:309–323, 1974.PubMedCrossRefGoogle Scholar
  160. 160.
    Nicholls, D.P., et al. Comparison of labetalol and propranolol in hypertension. Br. J. CLin. Pharmacol. 9:233–237, 1980.PubMedCrossRefGoogle Scholar
  161. 161.
    Survey Control Unit. Central Statistical Office. Ask a silly question. Government Statistical Service HMSO, 1976.Google Scholar
  162. 162.
    Bennett, A.E., and Ritchie, K. Questionnaires in medicine: A guide to their design and use. Oxford: Nuff, Prov. Hosp. Trust. 1975.Google Scholar
  163. 163.
    Tinker, M.A. In: Bases for effective reading. Minneapolis, Minnesota Press, 1965.Google Scholar
  164. 164.
    Clark, H.H. Psychol. Rev. 76:387, 1969.CrossRefGoogle Scholar
  165. 165.
    International nonproprietary names (INN) for pharmaceutical substances: WHO, 1976.Google Scholar
  166. 166.
    Bulpitt, C.J., et al. The symptom patterns of treated diabetic patients. J. Chron. Dis. 29:571–583, 1976.PubMedCrossRefGoogle Scholar
  167. 167.
    Bloch, A. Murphy’s law and other reasons why things go wrong. London, Magnum books, Methuen Paperbacks, 1979.Google Scholar
  168. 168.
    Amery, A., et al. Antihypertensive therapy in patients above age 60: Third interim report of the European Working Party on High Blood Pressure in Elderly (EWPHE). Acta Cardiol. 33:113–134, 1978.PubMedGoogle Scholar
  169. 169.
    Hampton, J.R. Presentation and analysis of the results of clinical trials in cardiovascular disease. Br. Med. J. 282:1371–1373, 1981.CrossRefGoogle Scholar
  170. 170.
    Norwegian Multicentre Study Group. Timolol-induced reduction in mortality and rein-farction in patients surviving acute myocardial infarction. N. Engl. J. Med. 301:801–807, 1981.Google Scholar
  171. 171.
    Wilkinson, G.N. Estimation of missing values for the analysis of incomplete data. Biometrics 14:257–286, 1958.CrossRefGoogle Scholar
  172. 172.
    Gordis, L. Conceptual and methodologic problems in measuring patient compliance. In: Compliance in health care, Haynes, R.L., Taylor, R.W., and Sackett, D.L. (eds.). Baltimore and London, John Hopkins University Press, 1979. Pp. 23–65.Google Scholar
  173. 173.
    Sackett, D.L. A compliance practical for the busy practitioner. In: Compliance in health care, Haynes, R.L., Taylor, R.W., and Sackett, D.L. (eds.). Baltimore and London, John Hopkins University Press, 1979. Pp. 286–294.Google Scholar
  174. 174.
    Feinstein, A.R., et al. A controlled study of three methods of prophylaxis against streptococcal infection in a population of rheumatic children. II. Results of the first three years of the study, including methods for evaluating the maintenance of oral prophylaxis. N. Engl. J. Med. 260:697–702, 1959.PubMedCrossRefGoogle Scholar
  175. 175.
    Park. L.C., and Lipman, R.S. A comparison of patient dosage deviation reports with pill counts. Psychoparmacologie 6:299–302, 1964.CrossRefGoogle Scholar
  176. 176.
    Gordis, L., Markowitz, M., and Lilienfeld, A.M. The inaccuracy in using interviews to estimate patient reliability in taking medications at home. Med. Care 7:49–54, 1969.PubMedCrossRefGoogle Scholar
  177. 177.
    Bulpitt, C.J., Clifton, P., and Hoffbrand, B.I. Factors influencing over and underconsumption of anti-hypertensive drugs. Acta Int. Pharmacodyn Ther. suppl.:243–250, 1980.Google Scholar
  178. 178.
    Mushlin, A.I., and Appel, F. A. Diagnosing potential noncompliance. Physicians’ ability in a behavioural dimension of medical care. Arch. Intern. Med. 137:318–321, 1977.PubMedCrossRefGoogle Scholar
  179. 179.
    Roth, H.P., Caron, H.S., and Hsi, B.P. Measuring intake of a prescribed medication: A bottle count and a tracer technique compared. Clin. Pharmacol. Ther. 11:288–337, 1970.Google Scholar
  180. 180.
    Bergman, A.B., and Werner, R.J. Failure of children to receive penicillin by mouth. N. Engl. J. Med. 268:1334–1338, 1963.PubMedCrossRefGoogle Scholar
  181. 181.
    Goldsmith, C.H. The effect of compliance distributors on therapeutic trial. In: Compliance in health care, Haynes, R.L., Taylor, R.W., and Sackett, D.L. (eds.). Baltimore and London, John Hopkins University Press, 1979. Pp. 297–308.Google Scholar
  182. 182.
    Feinstein, A.R. Biostatistical problems in ‘compliance bias’. Clin. Pharmacol. Ther. 16:846–857, 1974.PubMedGoogle Scholar
  183. 183.
    Schor, S., and Karten, I. Statistical evaluation of medical journal manuscripts. JAMA 195:1123–1128, 1966.PubMedCrossRefGoogle Scholar
  184. 184.
    Schoolman, H.M., et al. Statistics in medical research: principles versus practices. J. Lab. Clin. Med. 7:357–367, 1968.Google Scholar
  185. 185.
    Lionel, N.D.W., and Herxheimer, A. Assessing reports of therapeutic trials. Br. Med. J. 3:637–640, 1970.PubMedCrossRefGoogle Scholar
  186. 186.
    Gore, S.M., Jones, I.G., and Rytter, E.C. Misuse of statistical methods: critical assessment of articles in B.M.J. from January to March 1976. Br. Med. J. 1:85–87, 1977.PubMedCrossRefGoogle Scholar
  187. 187.
    Freiman, J.A., et al. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 ‘negative’ trials. N. Engl. J. Med. 299:690–694, 1978.PubMedCrossRefGoogle Scholar
  188. 188.
    Glantz, S.A. Biostatistics: How to detect, correct and prevent errors in the medical literature. Circulation 61:1–7, 1980.PubMedCrossRefGoogle Scholar
  189. 189.
    Armitage, P. Statistical methods in medical research. Oxford and Edinburgh, Blackwell Scientific, 1971.Google Scholar
  190. 190.
    Snedecor, G.W., and Cochran, W.G. Statistical methods. Ames, Iowa, Iowa State University Press, 1967.Google Scholar
  191. 191.
    Petrie, A. Lecture notes on medical statistics. Oxford and Edinburgh, Blackwell Scientific, 1978.Google Scholar
  192. 192.
    Peto, R., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: Analysis and examples. Br. J. Cancer 35:1–39, 1977.PubMedCrossRefGoogle Scholar
  193. 193.
    Hogben, L., and Sim, M. The self-controlled and self-recorded clinical trial for low-grade morbidity. Br. J. Prev. Soc. Med. 7:163–179, 1953.PubMedGoogle Scholar
  194. 194.
    Bulpitt, C.J. The design of clinical trials. Br. J. Hosp. Med. 13:611–620, 1975.Google Scholar
  195. 195.
    Feinstein, A.R. Clinical biostatistics. A survey of the statistical procedures in general medical journals. Clin. Pharmacol. Ther. 15:97–107, 1974.PubMedGoogle Scholar
  196. 196.
    Zar, J.H. In: Biostatistical analysis. Englewood Cliffs, N.J., Prentice-Hall, 1974. Pp. 130–131.Google Scholar
  197. 197.
    Nie, N.N., et al. Statistical package for the social sciences. New York, McGraw-Hill, 1975.Google Scholar
  198. 198.
    Healy, M.J.R., and Whitehead, T.P. Outlying values in the national quality control scheme. Ann. Clin. Biochem. 17:78–81, 1980.PubMedGoogle Scholar
  199. 199.
    Barnett, V. The study of outliers: Purpose and model. Appl. Stat. 27:242–250, 1978.CrossRefGoogle Scholar
  200. 200.
    John, J.A. Outliers in factorial experiments. Appl. Stat. 27:111–119, 1978.CrossRefGoogle Scholar
  201. 201.
    Sprackling, M.E., et al. Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. Br. Med. J. 283:1151–1153, 1981.CrossRefGoogle Scholar
  202. 202.
    Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50:163–170, 1966.PubMedGoogle Scholar
  203. 203.
    Breslow, N.E. Analysis of survival data under the proportional hazards model. Int. Stat. Rev. 43:45–57, 1975.CrossRefGoogle Scholar
  204. 204.
    Wulff, H.R. Letter: Confidence limits in evaluating controlled therapeutic trials. Lancet 2:969–970, 1973.PubMedCrossRefGoogle Scholar
  205. 205.
    Leading article. Interpreting clinical trials. Br. Med. J. 2:1318, 1978.Google Scholar
  206. 206.
    Baber, N.S., and Lewis, J.A. Beta-blockers in treatment of myocardial infarction. Br. Med. J. 2:59, 1980.CrossRefGoogle Scholar
  207. 207.
    Gore, S.M. Statistics in question: Assessing methods—confidence intervals. Br. Med. J. 283:660–662, 1981.CrossRefGoogle Scholar
  208. 208.
    Ederer, F. A parametric estimate of the standard error of the survival rate. J. Am. Stat. Assoc. 56:111–118, 1961.CrossRefGoogle Scholar
  209. 209.
    Cox, D.R. Regression models and life tables. J. R. Stat. Soc. Br. 34:187–202, 1972.Google Scholar
  210. 210.
    McMichael, J. Anticoagulants: Another view. Br. Med. J. 2:1007, 1964.PubMedCrossRefGoogle Scholar
  211. 211.
    Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. II. Mortality by race-sex and age. JAMA 242:2572–2577, 1979.CrossRefGoogle Scholar
  212. 212.
    Amery, A., et al. Hypotensive action and side effects of clonidine-chlorthalidone and methyldopa-chlorthalidone in treatment of hypertension. Br. Med. J. 4:392–395, 1970.PubMedCrossRefGoogle Scholar
  213. 213.
    McMahon, F.G. Efficacy of an antihypertensive agent. Comparison of methyldopa and hydrochlorothiazide in combination and singly. JAMA 231:155–158, 1975.PubMedCrossRefGoogle Scholar
  214. 214.
    Gibb, W.E., et al. Comparison of bethanidine, alpha-methyldopa and reserpine in essential hypertension. Lancet 2:275–277, 1970.PubMedCrossRefGoogle Scholar
  215. 215.
    Hefferman, A., et al. A within-patient comparison of debrisoquine and methyldopa in hypertension. Br. Med. J. 1:75–78, 1971.CrossRefGoogle Scholar
  216. 216.
    Conolly, M.E., et al. A crossover comparison of clonidine and methyldopa in hypertension. Eur. J. Clin. Pharmacol. 4:222–227, 1972.CrossRefGoogle Scholar
  217. 217.
    Oates, J. A., et al. The relative efficacy of guanethidine, methyldopa and pargyline as antihypertensive agents. N. Engl. J. Med. 273:729–734, 1965.PubMedCrossRefGoogle Scholar
  218. 218.
    Prichard, B.N.C., et al. Bethanidine, guanethidine and methyldopa in treatment of hypertension: A within patient comparison. Br. Med. J. 1:135–144, 1968.PubMedCrossRefGoogle Scholar
  219. 219.
    Schooler, K.K. A study of errors and bias in coding responses to open end questions. Dissertation Abstr. 16:2542, 1956.Google Scholar
  220. 220.
    Young, D.W. Evaluation of a questionary. Methods Inf. Med. 11:15–19, 1972.PubMedGoogle Scholar
  221. 221.
    Collen, M.F., et al. Reliability of a self-administered medical questionnaire. Arch. Intern. Med. 123:664–681, 1969.PubMedCrossRefGoogle Scholar
  222. 222.
    Rose, G.A. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull. WHO 27:645–658, 1962.PubMedGoogle Scholar
  223. 223.
    Maccoby, E.E., and Maccoby, N. The interview: A tool of social science. In: Handbook of social pychology, Lindzey, G. (ed.). Reading, Mass., Addison-Wesley, 1954.Google Scholar
  224. 224.
    Mellner, C. The self-administered medical history. Theoretical possibilities and practical limitations of the usefulness of standardized medical histories. Acta Chir Scand. Suppl. 406:1+, 1970.Google Scholar
  225. 225.
    Belson, W., and Duncan, J.A. A comparison of the check-list and the open response questioning systems. Appl. Stat. 11:120–132, 1962.CrossRefGoogle Scholar
  226. 226.
    Cannel, C.F., and Kahn, R.L. The collection of data by interviewing. In: Research Methods in Behavioral Sciences, Festinger, L., and Katz, D. (eds.). New York, Dryden, 1953.Google Scholar
  227. 227.
    Cronbach, L.J. Further evidence on response sets and test design. Educ. Psych. Meas. 10:3, 1950.Google Scholar
  228. 228.
    Anderson, J., and Day, J.L. New self-administered medical questionary. Br. Med. J. 4:636–638, 1968.PubMedCrossRefGoogle Scholar
  229. 229.
    Anastasi, A. In: Psychological testing. New York, Macmillan, 1961.Google Scholar
  230. 230.
    Parten, M.B. In: Surveys, polls and samples. New York, Harper, 1950.Google Scholar
  231. 231.
    Shepherd, M. Implications of a multi-centred clinical trial of treatment of depressive illness. In: Anti-depressant drugs, Garattini, S., and Dukes, M.N.G. (eds.). Amsterdam, Excerpta Medica, 1967. P. 332.Google Scholar
  232. 232.
    Hamilton, M. Evaluation of psychotropic drugs (3) sedatives. In: Principles and practice of clinical trials, Harris, E.L., Fitzgerald, J.D., (eds.). Edinburgh and London, E. and S. Livingston, 1970. Pp. 217–225.Google Scholar
  233. 233.
    Eysenck, H.J. Manual of the Maudsley personality inventory. London: University of London Press, 1959.Google Scholar
  234. 234.
    Taylor, J.A. A personality scale of manifest anxiety: J. Abnorm. Soc. Psychol. 48:285, 1953.CrossRefGoogle Scholar
  235. 235.
    Overall, J.E., and Gorham, G.R. The brief psychiatric rating scale. Psychol. Rep. 10:799, 1962.CrossRefGoogle Scholar
  236. 236.
    Kellner, R., and Sheffield, B.F. The use of self-rating in a single-patient multiple cross-over trial. Br. J. Psychiat. 114:193–196, 1968.CrossRefGoogle Scholar
  237. 237.
    Hamilton, M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 32:50, 1959.PubMedCrossRefGoogle Scholar
  238. 238.
    Shepherd, M. Evaluation of psychotropic drugs. In: Principles and practice of clinical trials. Harris, E.L., and Fitzgerald, J.D. (eds.). Edinburgh and London, E. and S. Livingston, 1970. Pp. 208–216.Google Scholar
  239. 239.
    Bulpitt, C.J. Quality of life in hypertensive patients. In: Hypertensive cardiovascular disease: Pathophysiology and treatment, Amery, A. et al. (eds.). The Hague, Martinus Nijhoff, 1982.Google Scholar
  240. 240.
    Bulpitt, C.J., Dollery, C.T., and Hoffbrand, B.I. The contribution of psychological features to the symptoms of treated hypertensive patients. Psychol. Med. 77:661–665, 1977.CrossRefGoogle Scholar
  241. 241.
    Bulpitt, C.J., et al. The symptom patterns of treated diabetic patients. J. Chron. Dis. 29:571–583, 1976.PubMedCrossRefGoogle Scholar
  242. 242.
    Fanshel, S., and Bush, J.W. A health status index and its application to health services outcomes. Operations Res. 18:1021–1065, 1970.CrossRefGoogle Scholar
  243. 243.
    Greenwood, D.T., and Todd, A.H. From laboratory to clinical use. In: Clinical trials. Johnson, F.N., and Johnson, S. (eds.). Oxford, Blackwell Scientific Publications, 1977, Pp. 13–35.Google Scholar
  244. 244.
    Simon, T.R.M., and Jones, G. Safety of medicines: The control of clinical trials. In: Clinical trials. Johnson, F.N., and Johnson, S. (eds.). Oxford, Blackwell Scientific Publications, 1977. Pp. 1–2.Google Scholar
  245. 245.
    Griffin, J.P., and Long, J.R. New procedure affecting the conduct of clinical trials in the United Kingdom. Br. Med. J. 283:477–478, 1981.CrossRefGoogle Scholar
  246. 246.
    Dollery, C.T. Clinical trials of new drugs. J. Roy. Coll. Phys. 11:226–233, 1977.Google Scholar
  247. 247.
    Lumbroso, A. The introduction of new drugs. In: Pharmaceuticals and health policy, Blum, R., et al. (eds.). London, Croom Helm, 1981.Google Scholar
  248. 248.
    Crout, J.R. Quoted in Lumbroso, A. The introduction of new drugs. In: Pharmaceuticals and health policy, Blum, R., et al. (eds.). London, Croom Helm, 1981.Google Scholar
  249. 249.
    Silverman, M., and Lydecker, M. The promotion of prescription drugs and other puzzles. In: Pharmaceuticals and health policy, Blum, R., et al. (eds.). London, Croom Helm, 1981. Pp. 78–92.Google Scholar
  250. 250.
    Lionel, W., and Herxheimer, A. Coherent policies on drugs: Formulation and implementation. In: Pharmaceuticals and health policy. Blum, R., et al. (eds.). London, Croom Helm, 1981. P. 240.Google Scholar
  251. 251.
    WHO. Tech. Rep. Ser. 425:5, 1969.Google Scholar
  252. 252.
    Bulpitt, C.J. Screening for adverse drug reactions. Br. J. Hosp. Med. 18:329–334, 1977.PubMedGoogle Scholar
  253. 253.
    Böttiger, L.E., and Westerholm, B. Drug-induced blood dyscrasias in Sweden. Br. Med. J. 3:339–343, 1973.PubMedCrossRefGoogle Scholar
  254. 254.
    Multicentre international study: Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade. Supplementary Report. Br. Med. J. 2:419–421, 1977.CrossRefGoogle Scholar
  255. 255.
    Skegg, D.C.G., and Doll, R. The case for recording events in clinical trials. Br. Med. J. 2:1523–1524, 1977.PubMedCrossRefGoogle Scholar
  256. 256.
    Lewis, J.A. Post marketing surveillance: How many patients? Tips (April):93–94, 1981.Google Scholar
  257. 257.
    Vere, D.W. Controlled trials to detect efficacy and toxicity: Training to meet tomorrow’s needs. In: Principles and practice of clinical trials. Harris, E.L., and Fitzgerald, J.D. (eds.). Edinburgh and London, E. and S. Livingston, 1970. Pp. 242–249.Google Scholar
  258. 258.
    Mann, R.D., et al. The significance of variations in the serum transaminases in the assessment of two new drugs. In: ‘Experimental studies and clinical experience—the assessment of risk. Proc. Eur. Soc. for the Study of Drug Toxicity, vol. VI. Amsterdam, Excerpta Medica Foundation, 1965.Google Scholar
  259. 259.
    The coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231:360–381, 1975.CrossRefGoogle Scholar
  260. 260.
    Knatterud, G.L., et al. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. IV. A preliminary report on phenformin results. JAMA 217:777–784, 1971.PubMedCrossRefGoogle Scholar
  261. 261.
    Oliver, M.F. Serum chloesterol—the knave of hearts and the joker. Lancet 2:1090–1095, 1981.PubMedCrossRefGoogle Scholar
  262. 262.
    The Anturane Reinfarction Trial Research Group: Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N. Engl. J. Med. 302:250–256, 1980.CrossRefGoogle Scholar
  263. 263.
    Armitage, P. Trials of antiplatelet drugs: some methodological considerations. Rev. Epidemiol Sante Publique 27:87–90, 1979.PubMedGoogle Scholar
  264. 264.
    Braunwald, E. Treatment of the patient after myocardial infarction. The last decade and the next. N. Engl. J. Med. 302:290–292, 1980.PubMedCrossRefGoogle Scholar
  265. 265.
    Kolata, G.B. FDA says no to Anturane. Science 208:1130–1132, 1980.PubMedCrossRefGoogle Scholar
  266. 266.
    Mitchell, J.R.A. Secondary prevention of myocardial infarction. The present state of the ART. Br. Med. J. 2:1128–1130, 1980.CrossRefGoogle Scholar
  267. 267.
    European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction. Streptokinase in acute myocardial infarction. N. Engl. J. Med. 301:797–802, 1979.CrossRefGoogle Scholar
  268. 268.
    Leading Article. Fibrinolytic therapy in myocardial infarction. Br. Med. J. 2:1017–1018, 1979.CrossRefGoogle Scholar
  269. 269.
    Elwood, P.C. Aspirin, dipyridamole and secondary prevention. In: The clinical impact of betaadrenoceptor blockade, Burley, D.M., and Birdwood, G.F.B. (eds.). Horsham, England, Ciba Laboratories, 1980. Pp. 25–26.Google Scholar
  270. 270.
    Elwood, P.C., et al. A randomised controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br. Med. J. 1:436–440, 1974.PubMedCrossRefGoogle Scholar
  271. 271.
    Coronary Drug Project Research Group: Aspirin in coronary disease. J. Chron. Dis. 29:625–642, 1976.CrossRefGoogle Scholar
  272. 272.
    Uberla, K. In: Acetylsalicylic acid in cerebral ischaemia and coronary heart disease. IV. Colfarit Symposium Berlin 1977. Stuttgart and New York, Schattauer Verlag, 1978. P. 157.Google Scholar
  273. 273.
    Elwood, P.C., and Sweetnam, P.M. Aspirin and secondary mortality after myocardial infarction. Lancet 2:1313–1315, 1979.PubMedCrossRefGoogle Scholar
  274. 274.
    Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 62:449–461, 1980.CrossRefGoogle Scholar
  275. 275.
    Aspirin Myocardial Infarction Study Group: A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 243:661–669, 1980.CrossRefGoogle Scholar
  276. 276.
    Sixty Plus Reinfarction Study Research Group: A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 2:989–993, 1980.Google Scholar
  277. 277.
    Vedin, J. A. Analysis presented at the VIIIth European Congress of Cardiology. Paris, 1980.Google Scholar
  278. 278.
    Reynolds, J.L., and Whitlock, R.M. Effects of beta-adrenergic receptor blocker in myocardial infarction for one year from onset. Br. Heart J. 34:252–259, 1972.PubMedCrossRefGoogle Scholar
  279. 279.
    Ahlmark, G., and Saetre, H. Long-term treatment with β-blocker after myocardial infarction. Eur. J. Clin. Pharmacol. 10:77–83, 1976.PubMedCrossRefGoogle Scholar
  280. 280.
    Wilhelmsson, C., et al. Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. Lancet 2:1157–1160, 1974.PubMedCrossRefGoogle Scholar
  281. 281.
    Andersen, M.P., et al. Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Preliminary results. Lancet 1:865–868, 1979.CrossRefGoogle Scholar
  282. 282.
    Hampton, J.R. Evidence on use of beta-blockers. In: Current themes in cardiology, Birdwood, G.F.B., and Russel, J.G. (eds.). Horsham, England, Geigy Pharmaceuticals, 1981. Pp. 86–89.Google Scholar
  283. 283.
    Beta blocker heart attack study group. The beta blocker heart attack trial. JAMA 246:2073–2074, 1981.CrossRefGoogle Scholar
  284. 284.
    Schor, S. The university group diabetes program. A statistician looks at the mortality results. JAMA 217:1671–1675, 1971.PubMedCrossRefGoogle Scholar
  285. 285.
    Feinstein, A.R. An analytic appraisal of the university group diabetes program (UGDP) study. Clin. Pharmacol. Ther. 12:167–191, 1971.PubMedGoogle Scholar
  286. 286.
    Data has holes, statistical men report to USV. Drug Trade News, 23 August 1971.Google Scholar
  287. 287.
    Cornfield, J. The University Group Diabetes Program. A further statistical analysis of the mortality findings. JAMA 217:1676–1687, 1971.PubMedCrossRefGoogle Scholar
  288. 288.
    Committee for the assessment of biometric aspects of controlled trials of hypoglycemic agents. JAMA 231:585–608, 1975.Google Scholar
  289. 289.
    Douglas-Jones, A.P., and Cruickshank, J.M. Once daily dosing with atenolol in patients with mild or moderate hypertension. Br. Med. J. 1:990–991, 1976.PubMedCrossRefGoogle Scholar
  290. 290.
    Bulpitt, C.J., and Rose, G.A. Design and conduct of clinical trials. In: The hypertensive patient. Marshall, A.J., and Barritt, D.W. (eds.). Tunbridge Wells, Pitman Medical, 1980. Pp. 494–505.Google Scholar
  291. 291.
    Harris, W.H. et al. Aspirin prophylaxis of venous thromboembolus after total hip replacement. N. Engl. J. Med. 297:1246–1249, 1977.PubMedCrossRefGoogle Scholar
  292. 292.
    Cranberg, L. Do retrospective controls make clinical trials ‘inherently fallacious’? Br. Med. J. 2:1265–1266, 1979.PubMedCrossRefGoogle Scholar
  293. 293.
    Leading article. Randomised controlled trials? Br. Med. J. 4:1244–1245, 1979.Google Scholar
  294. 294.
    Woolf, B. On estimating the relationship between blood group disease. Ann. Hum. Genet. 19:251–253, 1955.PubMedCrossRefGoogle Scholar
  295. 295.
    Mantel, N., and Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22:719–748, 1959.PubMedGoogle Scholar
  296. 296.
    Mittra, B. Potassium, glucose and insulin in treatment of myocardial infarction. Lancet 2:607–609, 1965.PubMedCrossRefGoogle Scholar
  297. 297.
    Hargreaves, M.A., and Maxwell, C. The speed of action of desipramine: a controlled trial. Intl. J. Neuropsychiat. 3:140–141, 1961.Google Scholar
  298. 298.
    Maxwell, C. Clinical trials, reviews, and the journal of negative results. Br. J. Clin. Pharmacol. 1:15–18, 1981.CrossRefGoogle Scholar
  299. 299.
    Rogers, S.C., and Clay, P.M. A statistical review of controlled trials of imipramine and placebo in the treatment of depressive illness. Br. J. Psychiat. 127:599–603, 1975.CrossRefGoogle Scholar
  300. 300.
    Fincke, M. Arzneimittelprüfung: Strafbare Versuchsmethoden. Heidelberg/Karlsruhe, 1977.Google Scholar
  301. 301.
    Leading Article. Controlled trials: Planned deception? Lancet 1:534–535, 1979.Google Scholar
  302. 302.
    Goldzieher, J.W. et al. A double-blind cross-over investigation of the side effects attributed to oral contraceptives. Fertil. Steril. 22:609–623, 1971.PubMedGoogle Scholar
  303. 303.
    Pryce, I.G. Clinical research upon mentally ill subjects who cannot give informed consent. Br. J. Psychiat. 133:366–369, 1978.CrossRefGoogle Scholar
  304. 304.
    Black, D. The paradox of medical care. J. Roy. Coll. Phycns. Lond. 13:57–65, 1979.Google Scholar
  305. 305.
    Cochrane, A.L. Attitudes to controlled trials. Paper presented at the 9th International Scientific Meeting of the IEA. Edinburgh, August 1981.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1983

Authors and Affiliations

  • Christopher J. Bulpitt
    • 1
    • 2
    • 3
  1. 1.Department of Medical Statistics and EpidemiologyLondon School of Hygiene and Tropical MedicineLondonUK
  2. 2.Royal Postgraduate Medical SchoolLondonUK
  3. 3.Hammersmith HospitalLondonUK

Personalised recommendations